Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

ase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned, including any further clinical trials of any of the Company's product candidates; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Quarterly Report on Form 10-Q filed with the SEC for the quarter ended June 30, 2007 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking sta
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... NJ (PRWEB) March 29, 2015 As ... deadlines often required by our pharmaceutical manufacturing clients, Whitehouse ... its sponsorship of the Berkenstock Race Team for the ... requires not only speed, but a strong sense of ... principles that lead to success in the quality control ...
(Date:3/27/2015)... 27, 2015   SurePure, Inc . (OTCQB: ... today that the Company has completed the verification ... of SurePure ("SURP") securities on OTCQB, an electronic ... and development stage companies. On March ... eligibility requirements designed to improve marketplace integrity and ...
(Date:3/27/2015)... Governor Andrew M. Cuomo today announced ... - the world’s largest business idea competition with $5 ... $1 million, six $500,000 awards and four $250,000 awards. ... compete for prizes that will turn ideas with high ... York region. , "Last year's successful 43North competition ...
(Date:3/26/2015)... 2015  BioNano Genomics, Inc., the leader in genome ... as chief commercial officer. Salyer has more than 20 ... in life sciences. At BioNano, Salyer will oversee the ... platform to assemble a comprehensive view of complex genomes ... 32 institutions located in the United States ...
Breaking Biology Technology:Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3
... Qi Lu, former EVP of,Yahoo!, continues to dedicate his passion ... HYSTA, USA. HYSTA is greatly,honored to have Qi,s on-going commitment ... August, he had served more than 10,years, which was a ... that has not changed is his dedication to serve the ...
... RainDance Technologies,Inc., a provider of innovative droplet-based ... today dedicated its new headquarters and,operations building ... Keynoting the event was Sir Richard ... medicine and Founder and Chief Scientific Officer ...
... for NDA Resubmission ... Planned For First Quarter 2009, LEXINGTON, Mass., Sept. 26 ... has reached,agreement with the U.S. Food and Drug Administration (FDA) with ... to,re-submission (complete response) of the New Drug Application (NDA) for,NEBIDO(R) in ...
Cached Biology Technology:Update: HYSTA Announces Dr. Qi Lu to Continue on as President of HYSTA, USA 2RainDance Dedicates New Headquarters, Manufacturing Facility 2RainDance Dedicates New Headquarters, Manufacturing Facility 3Indevus and FDA Agree on Path Forward for NEBIDO(R) 2Indevus and FDA Agree on Path Forward for NEBIDO(R) 3Indevus and FDA Agree on Path Forward for NEBIDO(R) 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/16/2015)... , March 16, 2015 ... GmbH will present groundbreaking innovations in biometric identification ... Germany .      (Photo: ... biometric innovation is well at the forefront: the ... e-gate made in Germany . ...
(Date:3/11/2015)... , Mar. 11, 2015 Research and Markets ... the "Access Control Market by Product, Application & ... report to their offering. , This ... to reach $10.4 billion by 2020, with an estimated ... report covers the products types such as contact cards ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2
... in the treatment of cocaine overdoses and a new defense ... the groundbreaking research that will be unveiled at the American ... conference takes place Sunday, May 16 -Thursday, May 20 at ... A Possible Treatment for Cocaine Addiction ...
... from Mahidol University have developed a rapid, high-throughput screening ... related report by Munkongdee et al, "Rapid diagnosis of ... 2010 issue of The Journal of Molecular Diagnostics ... a genetic defect in the production of a component ...
... 11, 2010) -- Cell-cell junctions are multi-molecular complexes ... act as barriers to permeability, and allow intercellular transport. ... Cold Spring Harbor Laboratory Press, surveys current research on ... Rockefeller University) and W. James Nelson (Stanford University), both ...
Cached Biology News:Biotherapeutic Innovations on Display at AAPS National Biotechnology Conference 2
A robust formulation of Taq Polymerase supplied with a 10X colored reaction buffer which allows Direct Gel-Loading...
... Dinitro-5,5'-dithiodibenzoic acid , DTNB , Ellman's reagent ... , *CAS-No.: 69-78-3 *Storage: ... with a reactive grouping not present in the ... reagent which will react directly with the product ...
96 Well Base Plate...
... that has been shown to help maintain the ... by reverse transcription, in vitro RNA transcription, and ... tightly binds RNases in a 1:1 ratio. It ... as RNase A, RNase B, RNase C, and ...
Biology Products: